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Abstract 
Background: Gynaecomastia is associated with exposure to antiretroviral therapy (ART), in particular efavirenz. There 
is limited data on clinical characteristics of patients with ART-associated gynaecomastia in resource-limited settings 
and little guidance on the optimal management of this adverse drug reaction (ADR). We describe the clinical charac-
teristics, management and outcomes of gynaecomastia cases reported to the National HIV & Tuberculosis Health Care 
Worker Hotline in South Africa.
Methods: We identified all gynaecomastia cases in adolescent boys and men on ART reported to the hotline 
between June 2013 and July 2014. We collected follow up data telephonically at monthly intervals to document clini-
cal management and outcomes.
Results: We received 51 reports of gynaecomastia between June 2013 and July 2014; 11% of the 475 patient-specific 
ADR queries to the hotline. All patients were on efavirenz-based ART. Mean age was 34 years (standard deviation 12) 
and seven were adolescents. The median onset of gynaecomastia was 15 months after efavirenz initiation (interquar-
tile range 6–42). Gynaecomastia was bilateral in 29 patients (57%) and unilateral in 16 (31%). Serum testosterone was 
quantified in 25 of 35 patients with follow up data, and was low in 2 (8%). Efavirenz was replaced with an alternative 
antiretroviral in 29/35 patients (83%) and gynaecomastia improved in 20/29 (69%).
Conclusions: Gynaecomastia was a frequently reported ADR in our setting, occurring with prolonged efavirenz 
exposure. Testosterone was low in the minority of tested cases. Most clinicians elected to switch patients off efavirenz, 
and gynaecomastia improved in the majority.
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Background
Gynaecomastia, a benign proliferation of glandular breast 
tissue in males [1] is thought to result from an imbalance 
between oestrogens and androgens [1]. There are reports 
of gynaecomastia in HIV infected men before antiretrovi-
ral therapy (ART) was available, [2] but most reports are 
in men on ART. The estimated prevalence ranges from 
1.8 to 2.9% [3–5].
Early case reports and case series implicated nucleoside 
reverse transcriptase inhibitors (NRTIs) and protease 
inhibitors [5–8]. However, case control studies found 
that gynaecomastia was associated with exposure to the 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 
efavirenz, and the NRTIs stavudine and didanosine [3, 4, 
9]. Most reports of ART-associated gynaecomastia come 
from resource-rich settings, and there are few data from 
Africa and other resource-limited settings.
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We describe the clinical characteristics of HIV infected 
patients with ART-associated gynaecomastia reported 
to the National HIV & Tuberculosis (TB) Health Care 
Worker Hotline in South Africa, clinical investigation and 
management, clinical outcomes and time to improve-
ment and/or resolution of gynaecomastia.
Methods
We included all suspected gynaecomastia cases reported 
to the National HIV & TB Health Care Worker Hotline 
between June 2013 and July 2014. The hotline is based at 
the Medicines Information Centre, University of Cape 
Town, and provides telephonic advice to health care 
workers on the management of patients with HIV and/
or tuberculosis, including adverse drug reactions (ADRs). 
Details of the service have been described elsewhere [10].
We used a standardized data collection form to collect 
data on patient characteristics, clinical characteristics of 
gynaecomastia, serum testosterone results and medication 
history. We recorded the date of initiation of the current 
ART regimen and when gynaecomastia was first noted by 
the patient. We calculated time to onset of gynaecomas-
tia as the time interval from initiation of the current ART 
regimen to the date when gynaecomastia was first noted 
by the patient. In four cases where the date when gynae-
comastia was first noted was missing, we used the date of 
the hotline query to calculate time to gynaecomastia onset. 
We obtained follow-up information telephonically from the 
health care worker at one month and then monthly or at the 
next patient visit for at least 6  months. We classified out-
comes as resolved, improved (reduction in breast size and/
or pain), unchanged, deteriorated or unknown. All descrip-
tive analysis was performed using STATA version 13.
Results
Patient characteristics
The hotline received queries from health care workers 
about suspected gynaecomastia in 51 males between 
June 2013 and July 2014. This constituted 11% of the 475 
patient-specific ADR queries received by the hotline dur-
ing this period. The mean age of patients with suspected 
gynaecomastia was 34  years (SD 12) (Table  1). Adoles-
cents comprised 14% of the case series. At the time of 
reporting gynaecomastia to the hotline, 30/31 (97%) 
patients with a viral load result recorded were virologi-
cally suppressed (Table  1). Gynaecomastia onset was 
slow, occurring after a median of 15 months, (IQR 6–42) 
on ART. Gynaecomastia was bilateral in 57% of patients 
(Table 1).
Antiretroviral regimens and concomitant drugs
All gynaecomastia cases reported to the hotline were on 
efavirenz-containing ART. The NRTI backbone at the 
time of gynaecomastia onset was tenofovir and lami-
vudine/emtricitabine in 40 (78%) of patients, stavudine 
and lamivudine in 5 (10%), abacavir and lamivudine in 4 
(8%), zidovudine and lamivudine in 1 (2%) of patients and 
unknown NRTI backbone in 1 (2%) patient.
Sixteen patients (31%) were taking concomitant drugs 
previously described to cause gynaecomastia in addition 
to efavirenz: isoniazid in 11 patients, isoniazid and sta-
vudine in one patient, amlodipine and stavudine in one 
patient and stavudine in three patients.
Clinical investigations and patient outcomes
We obtained follow-up data on 35 patients (69%) with a 
median follow-up period of 4 months, (IQR 1–6).
Serum testosterone testing was performed in 25/35 
(71%) patients, of which 19 were within the normal 
range, two cases had low testosterone, two cases had 
elevated testosterone and in two cases the result was not 
recorded.
Twenty nine patients (83%) discontinued efavirenz: 27 
patients were switched to nevirapine and two patients 
were switched to lopinavir/ritonavir. Gynaecomastia 
resolved completely in 7 of these 29 patients, improved 
in 13 and was unchanged in two, with unknown outcome 
in 7.
Six patients continued efavirenz. Gynaecomastia 
improved in one patient and was unchanged in one 
patient, with unknown outcome in four patients.
Table 1 Patient characteristics and  description of  sus-
pected gynaecomastia cases
Patient characteristic N (%) (n = 51)
Age (years), mean ± SD 34 ± 12
Age category
 Adolescent (10–17 years) 7 (14%)
 Adult (≥18 years) 36 (71%)
 Unknown 8 (16%)
Baseline CD4 count before ART initiation (mm3), 
mean ± SD
188 ± 95
Current viral load
 Viral load (<50) 26 (51%)
 Viral load (51–399) 4 (8%)
 Viral load >400 1 (2%)
 Viral load unknown 20 (39%)
Characteristics of gynaecomastia
 Site
  Unilateral 16 (31%)
  Bilateral 29 (57%)
  Unknown 6 (12%)
  Breast pain present 10 (20%)
Gynaecomastia onset (months on ART), median [IQR] 15 [6–42]
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Median time to first improvement of gynaecomastia 
was 3 months (IQR 2–4, range1–8) (Fig.  1). Complete 
resolution occurred after a median of 6  months (IQR 
4–6, range 4–9).
Discussion
We describe a case series of 51 patients with gynaecomas-
tia on efavirenz-based ART in South Africa. Efavirenz is 
the recommended NNRTI in the standard first-line ART 
regimen for adults in South Africa [11]. These cases were 
reported to the National HIV & TB Health Care Worker 
Hotline and comprised 11% of patient-specific ADR 
queries over a 13 month period. In the 35 patients with 
follow-up data, the majority switched from efavirenz 
to an alternative antiretroviral, and the gynaecomastia 
improved after efavirenz withdrawal in 69%.
This is to our knowledge the largest case series of ART-
associated gynaecomastia cases reported from Sub-Saha-
ran Africa. A small case series from Nigeria reported on 
six patients with efavirenz-associated gynaecomastia, 
all of which resolved after withdrawal of efavirenz [12]. 
Two cases of efavirenz-associated gynaecomastia were 
reported from Malawi, both of which improved after 
switching efavirenz to nevirapine [13].
Efavirenz is known to be associated with gynaeco-
mastia [3, 4, 9]. The proposed mechanism from in vitro 
data is that efavirenz mimics the effects of oestrogen on 
breast tissue [14]. Two other hypothesized mechanisms 
have been suggested for ART-associated gynaecomastia: 
immune restoration may increase breast tissue oestrogen 
availability, and efavirenz has been shown to increase the 
area under the curve of ethinyl oestradiol by at least 37%, 
thereby elevating the oestrogen–androgen ratio [15].
Three cohort studies from Spain and Italy have 
reported ART-associated gynaecomastia prevalence 
between 1.8 and 2.9% [3–5], whilst the incidence from 
another Spanish study of 1400 HIV infected men fol-
lowed up over 20  months was 2.4 per 100 person years 
on ART [6]. A study from Nigeria of 2920 HIV infected 
patients reported an incidence of gynaecomastia of 10.7 
per 100 person years over 8 years [16].
Interestingly 7 (14%) of our case series were adoles-
cents. In three of these adolescent patients, gynaecomas-
tia improved after withdrawal of efavirenz, suggesting that 
efavirenz was a probable contributing cause. However, the 
physiological changes of puberty may also have contrib-
uted to gynaecomastia in the adolescent cases we describe.
In contrast, previous case series do not report any 
cases of gynaecomastia in adolescents [6, 7, 12, 15, 17–
19]. Cross-sectional data from the general population 
has shown that gynaecomastia occurs in 4% of adoles-
cent boys aged 10–19 years [20]. There is limited data on 
ART-associated gynaecomastia in African children and 
adolescents [21, 22].
The clinical presentation of the gynaecomastia in our 
case series was primarily bilateral after several months 
on ART, as previously reported in other studies [6, 7, 
9, 12]. Previous studies have reported virological sup-
pression in 77–100% of patients at the time of onset of 
gynaecomastia [6, 8, 12, 15, 19]. In our case series 31 of 
the 51 patients had a current viral load result at the time 
of reporting gynaecomastia to the hotline, with viral load 
<400 copies/mL in 30/31 (97%).
The majority of patients were switched from efavirenz, 
after which gynaecomastia improved/resolved in the 
majority. This finding is similar to other case series where 
efavirenz was discontinued [12, 13, 15], but it is note-
worthy that other studies have reported improvement 
in patients, despite continuation of efavirenz [4, 8, 9]. 
Time to complete resolution was slow in our case series 
and was comparable to other studies that have reported 
a resolution time ranging from two to nine months [4, 6, 
8, 12, 15].
Where it was quantified, the free testosterone was 
normal in the majority of our gynaecomastia cases. In 
contrast, Biglia et  al. reported an association between 
hypogonadism and gynaecomastia [3]. Typically, the 
hotline recommends that a free testosterone be done 
to exclude hypogonadism before switching efavirenz to 
nevirapine. Free testosterone quantification is not rou-
tinely available in many resource-limited settings. The 
usefulness of testosterone testing in African patients with 
efavirenz-associated gynaecomastia needs to be explored 
further.
This case series has limitations. There was limited data 
on the method of diagnosis of the gynaecomastia cases. 
Follow-up information could not be obtained on all 
patients. Information on the exclusion of other causes 
Fig. 1 Kaplan Meier curve of time to improvement in patients with 
follow-up (n = 35)
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of gynaecomastia was not always available. Reports 
were collected and follow-up was done telephonically; 
hence patient histories, clinical findings and outcomes 
could not be verified by clinical assessment or by review 
of patient records. The cases we describe are not a ran-
dom and unbiased sample of gynaecomastia cases in 
our setting; they are cases in which a health care worker 
requested assistance from the hotline advice service.
Conclusions
In conclusion, efavirenz-associated gynaecomastia is 
frequently the subject of ADR queries to the HIV & TB 
Health Care Worker Hotline, suggesting that health care 
workers in South Africa need guidance on the manage-
ment of this ADR. In most cases, gynaecomastia cases 
reported to the hotline occurred after prolonged efa-
virenz exposure. Efavirenz was withdrawn in the majority 
of patients, in accordance with advice given by the hot-
line, and gynaecomastia improved slowly in the majority.
Further studies are needed to determine the incidence 
and risk factors of ART-associated gynaecomastia in 
African adolescents and adult men, the role of hypog-
onadism in gynaecomastia in this setting, and the opti-
mal clinical management of gynaecomastia. Studies 
answering these questions are essential in order to pro-
vide evidence-based guidance to health care workers on 
the optimal investigation and management of this impor-
tant treatment-limiting ADR.
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